Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 2 | 2023 | 112 | 1.570 |
Why?
|
| Models, Biological | 4 | 2013 | 642 | 1.240 |
Why?
|
| Buprenorphine | 1 | 2023 | 19 | 0.940 |
Why?
|
| Melanoma | 1 | 2023 | 91 | 0.850 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 151 | 0.810 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 214 | 0.730 |
Why?
|
| Proportional Hazards Models | 4 | 2023 | 423 | 0.640 |
Why?
|
| HIV Infections | 5 | 2022 | 2207 | 0.620 |
Why?
|
| Phytoplankton | 1 | 2013 | 5 | 0.470 |
Why?
|
| Humans | 22 | 2023 | 34853 | 0.470 |
Why?
|
| Anti-HIV Agents | 3 | 2021 | 394 | 0.440 |
Why?
|
| United States | 6 | 2023 | 3894 | 0.430 |
Why?
|
| Education, Medical | 2 | 2023 | 97 | 0.420 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 176 | 0.410 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 248 | 0.400 |
Why?
|
| Adult Stem Cells | 1 | 2010 | 12 | 0.390 |
Why?
|
| Embryonic Stem Cells | 1 | 2010 | 57 | 0.370 |
Why?
|
| SEER Program | 2 | 2023 | 87 | 0.350 |
Why?
|
| Students, Medical | 2 | 2021 | 121 | 0.330 |
Why?
|
| Multiple Myeloma | 1 | 2007 | 32 | 0.310 |
Why?
|
| Glioma | 1 | 2007 | 76 | 0.300 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 105 | 0.290 |
Why?
|
| Neoplasms | 2 | 2013 | 1033 | 0.280 |
Why?
|
| Poliomyelitis | 1 | 2005 | 7 | 0.270 |
Why?
|
| Spheroids, Cellular | 1 | 2005 | 28 | 0.260 |
Why?
|
| Tennessee | 2 | 2022 | 59 | 0.260 |
Why?
|
| Computer Simulation | 2 | 2021 | 347 | 0.240 |
Why?
|
| Mathematical Concepts | 2 | 2013 | 8 | 0.230 |
Why?
|
| Population Dynamics | 2 | 2013 | 29 | 0.230 |
Why?
|
| Systems Biology | 2 | 2013 | 20 | 0.230 |
Why?
|
| Nutrition Therapy | 1 | 2022 | 8 | 0.230 |
Why?
|
| Naloxone | 1 | 2023 | 50 | 0.230 |
Why?
|
| Models, Statistical | 2 | 2014 | 171 | 0.220 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 628 | 0.220 |
Why?
|
| Female | 10 | 2023 | 19873 | 0.210 |
Why?
|
| Skin | 1 | 2023 | 173 | 0.210 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 1426 | 0.210 |
Why?
|
| Cell Proliferation | 4 | 2013 | 1149 | 0.200 |
Why?
|
| Gastric Emptying | 1 | 2021 | 14 | 0.200 |
Why?
|
| Primary Health Care | 1 | 2023 | 283 | 0.200 |
Why?
|
| Atmospheric Pressure | 1 | 2020 | 9 | 0.190 |
Why?
|
| Pressure | 1 | 2020 | 36 | 0.190 |
Why?
|
| Retrospective Studies | 2 | 2023 | 1961 | 0.180 |
Why?
|
| Students, Dental | 1 | 2019 | 5 | 0.180 |
Why?
|
| Particulate Matter | 1 | 2020 | 49 | 0.180 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2021 | 87 | 0.180 |
Why?
|
| Air Pollution | 1 | 2020 | 59 | 0.180 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 39 | 0.180 |
Why?
|
| Treatment Outcome | 1 | 2023 | 1349 | 0.180 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 140 | 0.170 |
Why?
|
| Air Pollutants | 1 | 2020 | 90 | 0.170 |
Why?
|
| Students, Nursing | 1 | 2019 | 31 | 0.170 |
Why?
|
| Benzo(a)pyrene | 1 | 2020 | 122 | 0.170 |
Why?
|
| Physicians | 1 | 2021 | 148 | 0.170 |
Why?
|
| Medication Adherence | 1 | 2021 | 165 | 0.170 |
Why?
|
| Prejudice | 1 | 2019 | 101 | 0.170 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 255 | 0.170 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 118 | 0.170 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2019 | 123 | 0.170 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 181 | 0.160 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 186 | 0.160 |
Why?
|
| Antioxidants | 1 | 2021 | 386 | 0.160 |
Why?
|
| Liver | 1 | 2020 | 447 | 0.150 |
Why?
|
| Saliva | 1 | 2017 | 97 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 592 | 0.130 |
Why?
|
| Appalachian Region | 1 | 2014 | 2 | 0.130 |
Why?
|
| Southeastern United States | 1 | 2014 | 48 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2014 | 74 | 0.130 |
Why?
|
| Logistic Models | 2 | 2017 | 894 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 233 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2014 | 110 | 0.120 |
Why?
|
| Algorithms | 2 | 2014 | 435 | 0.120 |
Why?
|
| Risk Factors | 4 | 2020 | 3414 | 0.120 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 30 | 0.120 |
Why?
|
| Texas | 1 | 2014 | 299 | 0.120 |
Why?
|
| Biomass | 1 | 2013 | 50 | 0.120 |
Why?
|
| Mortality | 1 | 2014 | 150 | 0.110 |
Why?
|
| Male | 5 | 2023 | 18870 | 0.110 |
Why?
|
| Light | 1 | 2013 | 180 | 0.110 |
Why?
|
| RNA Interference | 1 | 2013 | 225 | 0.110 |
Why?
|
| Temperature | 1 | 2013 | 275 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2012 | 322 | 0.100 |
Why?
|
| Receptor, erbB-2 | 1 | 2012 | 122 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 570 | 0.100 |
Why?
|
| Iodoacetates | 1 | 2010 | 2 | 0.100 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2010 | 16 | 0.100 |
Why?
|
| Carcinoma, Ehrlich Tumor | 1 | 2010 | 17 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 142 | 0.090 |
Why?
|
| Prognosis | 1 | 2012 | 707 | 0.090 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2010 | 54 | 0.090 |
Why?
|
| Schools, Medical | 2 | 2023 | 192 | 0.090 |
Why?
|
| Viral Load | 2 | 2021 | 300 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 781 | 0.080 |
Why?
|
| Animals | 4 | 2021 | 14307 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2021 | 628 | 0.070 |
Why?
|
| Adult | 3 | 2019 | 11034 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 1 | 2005 | 480 | 0.060 |
Why?
|
| Health Status Disparities | 2 | 2020 | 583 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 53 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 2561 | 0.050 |
Why?
|
| Educational Status | 1 | 2023 | 295 | 0.050 |
Why?
|
| Community Health Services | 1 | 2023 | 175 | 0.050 |
Why?
|
| Self Care | 1 | 2022 | 150 | 0.050 |
Why?
|
| Pyloric Antrum | 1 | 2021 | 5 | 0.050 |
Why?
|
| Acrolein | 1 | 2021 | 15 | 0.050 |
Why?
|
| Middle Aged | 3 | 2020 | 9642 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2022 | 333 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2021 | 51 | 0.050 |
Why?
|
| Curcumin | 1 | 2021 | 66 | 0.050 |
Why?
|
| Porosity | 1 | 2020 | 32 | 0.050 |
Why?
|
| Hydrocortisone | 1 | 2021 | 72 | 0.050 |
Why?
|
| Community Health Centers | 1 | 2020 | 45 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2021 | 73 | 0.050 |
Why?
|
| Weight Gain | 1 | 2021 | 128 | 0.050 |
Why?
|
| Solvents | 1 | 2020 | 93 | 0.050 |
Why?
|
| Bisexuality | 1 | 2023 | 202 | 0.050 |
Why?
|
| Stereoisomerism | 1 | 2020 | 162 | 0.050 |
Why?
|
| Fluorescence | 1 | 2020 | 117 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 61 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2021 | 287 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2019 | 120 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2019 | 148 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2020 | 207 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2021 | 897 | 0.040 |
Why?
|
| Gene Expression | 1 | 2021 | 639 | 0.040 |
Why?
|
| Water | 1 | 2020 | 283 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2020 | 1422 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 445 | 0.030 |
Why?
|
| Mice | 2 | 2021 | 5668 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2021 | 874 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 2021 | 438 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 1300 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2021 | 1802 | 0.030 |
Why?
|
| Refractive Errors | 1 | 2010 | 25 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 4012 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 5035 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2010 | 210 | 0.020 |
Why?
|
| Aged | 1 | 2019 | 6448 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 580 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2128 | 0.020 |
Why?
|